This content is from: Premium What’s Behind EcoR1’s Healthy Returns The one-time II Rising Star posted another strong gain in a year when many other life sciences hedge funds lost money. By Stephen Taub January 21, 2022
This content is from: Premium In 2021, Credit Was King Multiple credit funds enjoyed solid returns last year. By Stephen Taub January 19, 2022
This content is from: Premium These Hedge Funds Just Went From Best to Worst At least six hedge funds, including Woodson Capital Management, posted their worst-ever results in 2021 after huge gains in 2020. By Stephen Taub January 18, 2022
This content is from: Premium Senvest Bet Big on GameStop and Won. Here’s Where It’s Investing Now. The hedge fund firm, which posted better than an 85 percent net gain in 2021, identifies its current favorite stocks. By Stephen Taub January 18, 2022
This content is from: Premium Perceptive Posts Biggest Loss in Its History Joseph Edelman’s life sciences firm suffered a rare major setback last year. By Stephen Taub January 14, 2022
This content is from: Premium D1 Capital Surged in 2021, But Not for All Investors The Tiger Grandcub and Whale Rock heavily depended on private investments last year. By Stephen Taub January 13, 2022
